 |
ArchiveIcahn Needs To Ante Up More If He Really Wants Clorox (CLX, BIIB, HAIN, LGF, MMI, TTWO, PG, CL, AMLN, FDML, IEP)Posted by Todd Shriber at 11:52AM on July 29th
Shares of consumer products giant Clorox (CLX), the maker of its namesake bleach and Hidden Valley salad dressings, are fractionally lower today despite a Bloomberg News report that says corporate raider Carl Icahn may have to pony up another $600 million if…  This Week in Billionaires: Icahn Makes an Offer, Sprott is Going Global (CLX, BIIB, DYN, MMI, DIS, MSFT, XOM, TEVA, MON, CVS, GE, PG, WMT, AG, AUY, SLW)Posted by Eric Monte at 2:55PM on July 21st
Shares of Clorox (CLX) traded higher this week after billionaire investor Carl Icahn offered to acquire the consumer products giant for $10.2 billion. Icahn’s offer valued California-based Clorox at $76.50 a share, or a 12% premium to where the stock closed… Clorox Cleans Up As Icahn Offers $10.2B For The Company (CLX, AMLN, BIIB, MMI, REGN, CL, KMB, PG)Posted by Todd Shriber at 12:24PM on July 15th
Shares of Clorox (CLX), the maker of its namesake bleach and the Hidden Valley salad dressing brand, are soaring 7% after billionaire investor Carl Icahn offered to acquire the consumer products giant for $10.2 billion. Icahn’s offer values California-based Clorox at… No Biotech Bounce, But Human Genome Shines (HGSI, GSK, BMRN, BIIB, TTHI, SPPI, EXEL)Posted by Todd Shriber at 12:36PM on March 10th
Biotech stocks are following the broader market lower today as the Biotechnology Stocks Index is off 0.8%, but at least one Index member is putting in an impressive performance. Human Genome Sciences (HGSI) is surging 13% after the FDA approved the company’s… Credit Suisse Weighs In on Big-Cap Biotechs (HGSI, GILD, AMGN, CELG, BIIB, UTHR, GENZ)Posted by Jason Smith at 8:46AM on December 7th
The biotechnology sector is one of the more volatile and sometimes outright speculative corners of the market, as traders bet on trial results, FDA approvals, and marketing deals. However, there are a number of relative-large caps in the space that… Legendary Activist Investor Hikes Top Stakes in Q3 (LGF, CHK, HAIN, LWSN, MENT, MOT, REGN, DYN, MAT, FDML, GENZ, BIIB)Posted by Jason Smith at 10:52AM on November 29th
Legendary investor Carl Icahn, known for making aggressive moves in the market, hiked his firm’s bid for Lions Gate Entertainment (LGF) back in August, and with the deadline for end-of-Q3 regulatory filings behind us, investors can now see where else the billionaire… Icahn Ups Tech, Energy Exposure (APC, CHK, MENT, LWSN, HAIN, TTWO, MOT, GENZ, BIIB, AMLN)Posted by Max Magee at 9:07AM on August 23rd
Legendary investor Carl Icahn, known for making aggressive moves in the market, remained active in the biotech space while also opening modest new positions in the tech and energy sectors during Q2. Looking at Icahn’s top U.S.-listed, equity holdings at the end… Deutsche Bank Picks Winners In Volatile Biotech Sector (AMGN, BIIB, GENZ, CELG, GILD, DNDN)Posted by Jason Smith at 2:02PM on August 16th
The highly tradable biotech sector is often volatile as individual components fluctuate in relation to progress towards marketing approval, buyout speculation, or other catalysts. Given the tremendous amount of moving parts sector-wide, it can often be difficult to nail down… The Genzyme Price Speculation Begins (GENZ, SNY, GSK, WCRX, BAX, PFE, BIIB, AMGN, AGN, CEPH, CELG)Posted by Jason Smith at 1:17PM on July 26th
Last week, Genzyme (GENZ) shares soared on Friday on reports that pharma giant Sanofi-Aventis (SNY) may be interested in the biotech firm as an acquisition, and GlaxoSmithKline (GSK) was mentioned as another possible suitor on Monday. While no official announcements have been made… Times Talks Icahn As Billionaire’s Top Picks Outperform (LLY, AZN, BIIB, GENZ, AMLN, TTWO, GOOG, YHOO, PENN)Posted by Owen Vater at 10:56AM on March 22nd
Carl Icahn is one of the richest investors in the world, and some of his latest picks prove that the 74-year-old hasn’t lost his edge. Over the years Icahn has earned himself a reputation as a corporate raider, but he did…  |
|
Follow us on
  |
| Home | Find | Research | Track | Register | My Account | Logout | Web site design by LightMix |
| © 2007-2013 Indie research Corp. All rights reserved. |